Is Compounded Semaglutide the Same as Ozempic? The Honest Answer After Two Years of Running a GLP-1 Program

Disclaimer: Compounded semaglutide is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.

A patient who found our program last year shared that she had driven two hours each way to a weight loss clinic in another city, paid $1,200 out of pocket for a two-month supply of Ozempic, and then made the same drive again when her prescription ran out. She came to us after her third trip with a question our team hears constantly: is compounded semaglutide the same as Ozempic, and if so, why does ours cost less?

The short answer no. The longer answer is worth understanding, and my pharmaceutical background puts me in a position to explain it clearly — not as clinical guidance, but as someone who understands drug development, supply chains, and what actually drives price in this market.

What These Products Have in Common, and Where They Diverge

Ozempic and Wegovy are FDA-approved products whose active ingredient is semaglutide, a GLP-1 receptor agonist with a specific amino acid sequence and fatty acid side chain that gives it its long half-life of approximately seven days. Compounded semaglutide is formulated by a 503A pharmacy. It has not been reviewed or approved by the FDA, and its potency, purity, and clinical performance cannot be assumed to match the approved products.

That does not make them the same product. Compounded semaglutide has not been reviewed or approved by the FDA and is not the same finished drug product as Ozempic or Wegovy. Because it is not FDA-reviewed, the equivalence, potency, and purity assurances that apply to the approved products do not automatically apply to a compounded formulation. The delivery device, the formulation, the manufacturer, the price, and the supply chain all differ as well. Those are important distinctions, and I want to be direct about them.

For a cellular-level explanation of how semaglutide acts on the GLP-1 receptor, see How Semaglutide Works at a Cellular Level.

The Formulation Differences Are Real

Ozempic uses polysorbate 80 as a surfactant, along with a pH-buffered vehicle, disodium phosphate dihydrate, and sodium chloride. Compounded semaglutide typically uses bacteriostatic water or a comparable sterile vehicle as the diluent, with pH adjustment as appropriate. The excipients are different, the preparation is different, and the compounded product has not gone through the FDA’s review process for the finished drug product. Our clinical team discusses this with every patient before they start.

Why Brand Ozempic Costs So Much More

Ozempic’s U.S. list price of approximately $900 to $1,000 per month reflects patent exclusivity, decades of R&D investment, a global regulatory approval infrastructure, and a large commercial sales organization. That price is built on patent economics, not production cost.

Compounded semaglutide doesn’t carry any of that overhead. A 503A compounding pharmacy sources active pharmaceutical ingredient from an accredited supplier, prepares the medication in a licensed sterile compounding facility under USP Chapter 797 standards, and dispenses it under a valid prescription with documented clinical justification. The price reflects actual production cost rather than a patent return layered on top.

The international pricing comparison is instructive: Ozempic is available in Canada and the UK at a fraction of the U.S. price. Not because it is different there, but because most countries regulate pharmaceutical pricing and the U.S. largely does not.

The Regulatory Environment in 2026

From my pharmaceutical trade vantage point, the regulatory picture here has changed materially and patients deserve to understand it clearly. The FDA’s shortage-based pathway that permitted broad “essentially a copy” compounding of semaglutide ended when the shortage was declared resolved in February 2025. The operative framework now is the 503A patient-specific pathway, which permits compounding when a licensed prescriber documents a specific clinical reason the commercial product does not meet an individual patient’s need.

This is a narrower, more carefully documented practice than what existed during the shortage. Anyone offering compounded semaglutide without a clear clinical basis documented at the prescription level is not operating within that framework.

What I Think Every Patient Should Know Before Starting

One of the most consistent things I observe operationally is that patients don’t ask the right question early enough. They ask how much they’ll lose. They don’t ask what happens if they stop. GLP-1 therapy works while it is being taken, and appetite regulation tends to return toward baseline after stopping. Our clinical team frames this as a sustained management strategy rather than a finite course, so patients approach it with the right expectations from the start.

For patients weighing tirzepatide against semaglutide, see Tirzepatide vs Semaglutide, or review our compounded tirzepatide online program. For muscle preservation during weight loss, see The Protein and Resistance Training Protocol for GLP-1 Patients.

FAQ

Q: Is compounded semaglutide the same as Ozempic? No, they are not the same product. Compounded semaglutide is prepared by a 503A pharmacy and has not been reviewed or approved by the FDA, while Ozempic and Wegovy are FDA-approved products. The delivery device, formulation, manufacturer, regulatory status, price, and supply chain are all different. Because compounded semaglutide is not FDA-reviewed, its potency, purity, and clinical performance cannot be assumed to match the approved products. Our clinical team discusses this distinction with every patient.

Q: Is it still legal to prescribe compounded semaglutide? Under the 503A patient-specific framework, yes — when a licensed prescriber documents a specific clinical reason the commercial product does not meet that patient’s need. The shortage-based pathway that allowed broad compounding ended in April 2025.

Q: Why does Ozempic cost so much more? U.S. pharmaceutical pricing is largely unregulated at the product level. Ozempic’s price reflects patent exclusivity, R&D investment, and large commercial infrastructure. Semaglutide is available at substantially lower prices in most other countries. Compounded semaglutide reflects actual production cost without the patent economics.

Q: What happens to weight if someone stops GLP-1 therapy? Appetite regulation tends to return toward baseline after stopping, and many patients find weight returns without a maintenance plan in place. Our clinical team discusses this before anyone starts so expectations are grounded from the outset.

If you want to talk through whether this is right for you, our providers are available online. Start at precisiontelemed.com.

This post reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult one of our licensed providers for personalized clinical guidance.

Disclaimer: Compounded semaglutide is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. Compounded medications are not the same as commercially available FDA-approved products. This content reflects my perspective as a pharmaceutical executive and founder and is not medical advice. Consult one of our licensed providers for personalized clinical guidance.